Table 3. 8q24 CpG sites significantly associated with the risk of aggressive or non-aggressive prostate cancer (P _trend<0.05)a.

			Aggressive prostate cancerb		Non-aggressive prostate cancerb
CpG site coordinatec	Location	Quartiled	Ca/Co	OR (95% CI)e	Ca/Co	OR (95% CI)e	phete,f
Chr8:128753187	MYC
		1	34/176	REF	132/176	REF
		2	46/173	1.35 (0.82–2.22)	132/173	1.03 (0.74–1.42)
		3	42/175	1.21 (0.73–2.01)	110/175	0.84 (0.61–1.18)
		4	50/173	1.51 (0.92–2.49)	137/173	1.05 (0.76–1.45)
		Ptrendg (q-valueh)		0.02 (0.53)		0.70 (0.89)	0.01
Chr8:128753154	MYC
		1	34/176	REF	137/176	REF
		2	49/177	1.52 (0.93–2.50)	138/177	1.00 (0.73–1.38)
		3	33/174	1.07 (0.63–1.82)	121/174	0.88 (0.63–1.22)
		4	54/174	1.71 (1.05–2.78)	118/174	0.86 (0.62–1.19)
		Ptrendg (q-valueh)		0.03 (0.53)		0.20 (0.57)	4.6 × 10−3
Chr8:128428897	POU5F1B
		1	46/175	REF	142/175	REF
		2	32/173	0.69 (0.42–1.15)	138/173	0.98 (0.71–1.35)
		3	56/174	1.16 (0.74–1.83)	122/174	0.88 (0.63–1.22)
		4	38/174	0.80 (0.49–1.31)	110/174	0.78 (0.56–1.08)
		Ptrendg (q-valueh)		0.03 (0.53)		0.02 (0.28)	0.73
Chr8:128428931	POU5F1B
		1	46/174	REF	160/174	REF
		2	48/175	1.03 (0.65–1.64)	115/175	0.70 (0.51–0.97)
		3	35/174	0.78 (0.48–1.28)	113/174	0.69 (0.50–0.96)
		4	43/173	0.91 (0.57–1.46)	124/173	0.79 (0.57–1.08)
		Ptrendg (q-valueh)		0.05 (0.54)		0.04 (0.30)	0.67
Chr8:128428949	POU5F1B
		1	40/175	REF	159/175	REF
		2	37/175	0.88 (0.53–1.46)	124/175	0.78 (0.56–1.07)
		3	54/173	1.33 (0.83–2.13)	114/173	0.73 (0.53–1.02)
		4	41/174	0.99 (0.60–1.62)	116/174	0.73 (0.53–1.01)
		Ptrendg (q-valueh)		0.64 (0.91)		0.01 (0.28)	0.23
Chr8:128428915	POU5F1B
		1	49/174	REF	148/174	REF
		2	35/174	0.69 (0.42–1.14)	148/174	1.00 (0.73–1.37)
		3	46/174	0.98 (0.61–1.58)	109/174	0.71 (0.51–1.00)
		4	42/174	0.72 (0.44–1.17)	107/174	0.76 (0.54–1.07)
		Ptrendg (q-valueh)		0.07 (0.58)		0.05 (0.33)	0.72
Chr8:128428869	POU5F1B
		1	39/175	REF	145/175	REF
		2	48/174	1.24 (0.76–2.00)	132/174	0.92 (0.67–1.26)
		3	49/175	1.25 (0.77–2.03)	115/175	0.78 (0.57–1.09)
		4	35/173	0.83 (0.49–1.39)	118/173	0.84 (0.61–1.17)
		Ptrendg (q-valueh)		0.19 (0.70)		0.03 (0.28)	0.79
Chr8:128428978	POU5F1B
		1	38/175	REF	141/175	REF
		2	58/174	1.55 (0.96–2.49)	124/174	0.86 (0.62–1.19)
		3	37/174	0.90 (0.53–1.53)	144/174	1.02 (0.73–1.41)
		4	39/174	0.83 (0.48–1.45)	104/174	0.75 (0.52–1.08)
		Ptrendg (q-valueh)		0.40 (0.71)		0.03 (0.28)	0.40
Chr8:128012411	Intergenic
		1	38/174	REF	154/174	REF
		2	48/176	1.16 (0.71–1.91)	136/176	0.86 (0.62–1.18)
		3	42/172	1.08 (0.65–1.80)	111/172	0.71 (0.50–0.99)
		4	41/174	0.94 (0.56–1.59)	107/174	0.69 (0.49–0.98)
		Ptrendg (q-valueh)		0.86 (0.91)		7.1 × 10−3 (0.28)	0.11
Chr8:128444762	Intergenic
		1	52/177	REF	168/177	REF
		2	40/175	0.71 (0.44–1.14)	118/175	0.74 (0.53–1.01)
		3	36/174	0.67 (0.41–1.09)	123/174	0.76 (0.55–1.04)
		4	43/175	0.83 (0.52–1.33)	103/175	0.62 (0.45–0.86)
		Ptrendg (q-valueh)		0.24 (0.70)		0.03 (0.28)	0.82

Abbreviations: Ca=case; CI=confidence interval; Co=control; OR=odds ratio.

^aBolding denotes P<0.05.

^bAggressive prostate cancer was defined as Stage III/IV or Gleason score ⩾8.

^cNCBI37/hg19 coordinate.

^dQuartile cutpoints defined among controls.

^eAdjusted for age at draw and year of draw.

^fP-value for heterogeneity from Wald test.

^gP-value for CpG site variable entered in the model as a continuous variable.

^hFalse Discovery Rate adjusted P-value.